Project Grant R01HL182020
Award Date 8/15/26
Completion Date 5/31/30
Dollars Obligated $762K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Kingsville, TX 78363, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Texas A&M University System Health Science Center $758,499 on August 19, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate a novel beta-adrenergic signaling mechanism that drives interleukin 17A (IL-17A) production and hypertension during chronic stress. The research examines how repeated social defeat stress exacerbates blood pressure rise induced by angiotensin II through IL-17A overproduction by...
- Federal Grant Award Summary The University of Texas Health Science Center at Houston received a $234,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 15, 2025 through July 31, 2027. The research will investigate the force transduction mechanisms of leukocyte function-associated antigen-1 (LFA-1), a critical CD18 integrin that mediates immune cell adhesion, migration, and...
- The National Heart, Lung, and Blood Institute awarded Texas Tech University $594,288 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate YAP/TAZ signaling pathways in vascular smooth muscle cell adhesion and migration as a preventive and therapeutic strategy for atherosclerosis. The research comprises three aims. Aim 1 will define how extracellular matrix mechanics regulate vascular smooth muscle cell mechanotransduction. Aim 2 will assess how...
- The National Heart, Lung, and Blood Institute awarded Texas A&M University $2.214 million on September 11, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of GPI-anchor biosynthesis in sleep regulation. The project applies genomic, computational, and behavioral approaches to functionally validate sleep genes identified through human genome-wide association studies. The work includes identifying targets of the GPI-anchor biosynthesis pathway in...
- The National Heart, Lung, and Blood Institute awarded Texas A&M Engineering Experiment Station $405,966 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a multifunctional nanoparticle platform targeting galectin-3 for pulmonary fibrosis therapy. The recipient will optimize anti-fibrotic drug-containing, galectin-3-targeted poly(lactic-co-glycolic acid) nanoparticles for pulmonary delivery, building on prior results demonstrating nanoparticle...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $643,349 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 17, 2026, to investigate the role of gasdermin D (GSDMD) inhibition in reducing inflammation-related atrial fibrillation risk associated with clonal hematopoiesis and aging. The research employs bone marrow transplantation, deep cardiac phenotyping, single-cell transcriptomics, and genetic analyses to elucidate how clonal...
- The National Heart Lung and Blood Institute awarded The University of Texas Southwestern Medical Center $749,229 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the novel role of IgG glycosylation and endothelial FcγRIIB in cardiovascular complications in rheumatoid arthritis. The project examines how altered IgG glycosylation and endothelial cell dysfunction contribute to elevated cardiovascular disease and venous thromboembolism risk in...
- The National Heart, Lung, and Blood Institute awarded Thomas Jefferson University (operating as Sidney Kimmel Medical College) $763,379 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanisms of GRK5 regulation of G protein-coupled receptor signaling in platelets. The research addresses feedback regulation of GPCRs during platelet activation and the negative regulation of the thrombin receptor by GRK5, a kinase whose altered expression is...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $1,081,420 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct basic and translational research on platelet activation pathways and disorders of platelet count and function. The recipient will investigate cellular signaling pathways—particularly G proteins and integrin receptors—that control platelet adhesion and plug formation in hemostasis and...
- Federal Project Grant Award Summary Texas A&M University received a $217,281 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 15, 2025, with completion targeted for August 31, 2027. The award funds the development of statistical and computational tools to analyze rhythmic gene expression patterns and advance understanding of circadian rhythms—physiological, behavioral, and physical...